OncoCell MDx, Inc., a Royal Oak, Mich.-based pan-disease immunogenomics platform company developing novel noninvasive blood-based tests to optimize patient care, raised $22.2m in Series B financing.
The round was led by Savitr Capital with participation from existing investors.
The company, which has raised more than $30m to date, intends to use the funds to advance development and commercialization of its pan-disease diagnostic testing platform.
Led by Mark McDonough, President and CEO, OncoCell MDx is an immunogenomics platform company developing and commercializing novel noninvasive blood-based immunogenomic assays designed to aid physicians in understanding underlying disease pathology in prostate cancer and other disease.
The company’s proprietary technologies were created at Harvard Medical School by OncoCell MDx’s founder, Professor Amin I. Kassis.
OncoCell MDx plans to launch a blood test for detection and grading of aggressive prostate cancer next year.